Premium
Docetaxel‐based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival
Author(s) -
Nayyar Rishi,
Sharma Nitin,
Gupta Narmada P
Publication year - 2009
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2009.02351.x
Subject(s) - medicine , docetaxel , prednisone , prostate cancer , zoledronic acid , urology , prostate specific antigen , oncology , chemotherapy , cancer
Objectives: To evaluate the efficacy of docetaxel/prednisone and zoledronic acid in hormone refractory prostate cancer (HRPC) patients and to analyze prognostic factors predicting overall survival. Methods: Forty‐four HRPC patients were given docetaxel (75 mg/m 2 ), prednisone and zoledronic acid (4 mg) every three weeks. Overall and progression‐free survival curves were calculated. Using the log–rank test, variables predicting overall survival (age, Gleason score, baseline prostate‐specific antigen [PSA], percentage PSA decline, nadir PSA, number of chemotherapy cycles) were calculated. Results: Median age was 66 years and mean PSA 171.25 ng/mL. The average number of given cycles was 6.3. A good PSA response (>50% decline) was observed in 26/44 cases (59.1%). A total of 17/44 (38.6%) patients expired with a median overall survival of 62.4 weeks. Patients with a Gleason score less than 7, who received more than four cycles and with a more‐than‐50% decline in PSA had significantly better survival. Variables like age, baseline PSA and nadir PSA did not significantly affect survival. Conclusion: The combination of docetaxel/zoledronic/prednisone is safe and effective in the management of HRPC. Patients with a Gleason score <7, PSA decline >50% and those who receive more than four cycles have significantly better survival.